Greg Reh leads Deloitte’s global life sciences sector which includes clients in biopharma, medtech, generics and distribution businesses, as well as non-profit patient advocacy organizations and regulatory agencies. He discusses talent acquisition and retention in global life sciences today, the challenges around data and AI uptake, and the future of next-generation therapies.
The reality of how cell and gene therapies and some of the other novel therapies will enter the market with an outcomes-based reimbursement model is going to drive how the data to quantify outcomes is gathered and determined in the first place
